📣 VC round data is live. Check it out!

Lanxess Valuation Multiples

Discover Lanxess' revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like FMC, Anupam Rasayan India, De Nora, CAC Nantong Chemical Co and more.

Lanxess Overview

About Lanxess

Lanxess AG is a German chemical company that was originally spun out of Bayer. Lanxess has visibly decommoditised its portfolio by divesting its synthetic rubber business. It has business segments namely: specialty chemicals company in the fields of consumer protection chemicals, specialty additives, intermediates, and others. Geographically, it operates in EMEA (excluding Germany), Germany, Americas, and Asia-Pacific.


Founded

2004

HQ

Germany

Employees

12.3K

Sectors

Financials (LTM)

Revenue: $7B
EBITDA: $586M

EV

$4B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Lanxess Financials

Lanxess reported last 12-month revenue of $7B and EBITDA of $586M.

In the same LTM period, Lanxess generated $1B in gross profit, $586M in EBITDA, and had net loss of ($464M).

Revenue (LTM)


Lanxess P&L

In the most recent fiscal year, Lanxess reported revenue of $7B and EBITDA of $518M.

Lanxess is unprofitable as of last fiscal year, with gross margin of 20%, EBITDA margin of 7%, and net margin of (3%).

See analyst estimates for Lanxess
LTMLast FY202320242025202620272028
Revenue$7B$7B$8B$7B$7B
Gross Profit$1B$2B$1B$2B$1B
Gross Margin21%20%19%20%20%
EBITDA$586M$518M$169M$518M$587M
EBITDA Margin9%7%2%7%9%
EBIT Margin(0%)1%(1%)1%(0%)
Net Profit($464M)($206M)$515M($206M)($664M)
Net Margin(7%)(3%)7%(3%)(10%)
Net Debt-$3B---

Financial data powered by Morningstar, Inc.

Lanxess Stock Performance

Lanxess has current market cap of $2B, and enterprise value of $4B.

Market Cap Evolution


Lanxess' stock price is $18.91.

Lanxess share price decreased by 1.7% in the last 30 days, and by 35.1% in the last year.

Lanxess has an EPS (earnings per share) of $-2.39.

See more trading valuation data for Lanxess
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$4B$2B-1.6%-1.7%-14.2%-35.1%$-2.39

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Lanxess Valuation Multiples

Lanxess trades at 0.7x EV/Revenue multiple, and 7.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Lanxess

EV / Revenue (LTM)


Lanxess Financial Valuation Multiples

As of June 3, 2026, Lanxess has market cap of $2B and EV of $4B.

Lanxess has a P/E ratio of (3.5x).

LTMLast FY202320242025202620272028
EV/Revenue0.7x0.6x0.6x0.6x0.7x
EV/EBITDA7.5x8.5x26.1x8.5x7.5x
EV/EBITn/m75.7x(75.7x)75.7x(171.0x)
EV/Gross Profit3.2x2.9x3.0x2.9x3.4x
P/E(3.5x)(7.9x)3.2x(7.9x)(2.5x)
EV/FCF(208.3x)20.1x7.4x20.1x(72.4x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Lanxess Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Lanxess Margins & Growth Rates

Lanxess decreased revenue by 12% but EBITDA grew by 13% in the last fiscal year.

In the most recent fiscal year, Lanxess reported gross margin of 20%, EBITDA margin of 7%, and net margin of (3%).

See estimated margins and future growth rates for Lanxess

Lanxess Margins

Last FY202420252026202720282029
Gross Margin20%20%20%21%
EBITDA Margin7%7%9%9%
EBIT Margin1%1%(0%)0%
Net Margin(3%)(3%)(10%)(3%)
FCF Margin3%3%(1%)0%

Lanxess Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(12%)(5%)(12%)4%
Gross Profit Growth(13%)2%(13%)11%
EBITDA Growth13%207%13%(1%)
EBIT Growth(144%)(200%)(144%)(148%)
Net Profit Growth223%(140%)223%(71%)
FCF Growth(128%)(63%)(128%)(155%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Lanxess Operational KPIs

Lanxess' revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.

Lanxess' Rule of 40 is 13% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lanxess' Rule of X is 19% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Lanxess
LTMLast FY202320242025202620272028
Rule of 4012%13%---
Bessemer Rule of X16%19%---
Revenue per Employee-$0.6M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue14%14%14%14%15%
G&A Expenses to Revenue4%4%4%4%5%
R&D Expenses to Revenue2%2%1%2%2%
Opex to Revenue-20%20%20%-

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Lanxess Competitors

Lanxess competitors include FMC, Anupam Rasayan India, De Nora, CAC Nantong Chemical Co, Alpek, Ube, National Industralization, Ecovyst, Shanghai C&D Innostic and Advanced Petrochemical.

Most Lanxess public comparables operate across Chemicals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
FMC1.5x1.5x6.9x7.4x
Anupam Rasayan India11.3x8.9x39.5x36.0x
De Nora1.7x1.7x8.8x9.4x
CAC Nantong Chemical Co2.0x2.0x10.6x-
Alpek0.4x0.5x6.7x6.0x
Ube1.2x1.3x32.2x-
National Industralization4.2x3.9x(16.2x)(7.2x)
Ecovyst2.4x2.1x10.0x9.4x

This data is available for Pro users. Sign up to see all Lanxess competitors and their valuation data.

Start Free Trial

Acquisitions by Lanxess

Lanxess has acquired 6 companies to date.

Last acquisition by Lanxess was on August 24th 2021. Lanxess acquired International Flavors & Fragrances for $1B (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Lanxess

International Flavors & Fragrances
Emerald Performance Materials
Emerald Kalama Chemical
IMD Natural Solutions
Description
International Flavors & Fragrances is the largest specialty ingredients producer globally. It sells ingredients for the food, beverage, health, household goods, personal care, and pharmaceutical industries. The company makes proprietary formulations, partnering with customers to deliver custom solutions. Through its taste and scent segments, which each generate around 25% of profits, IFF is a leading flavor and fragrances producer. The health and biosciences business, which generates 30% of profits, is a global leader in probiotics and enzymes. The remaining profits come from the food ingredients business, which sells texturants, plant-based proteins, and other ingredients, though IFF plans to divest this business in the future.
Emerald Performance Materials is a Cuyahoga Falls-headquartered manufacturer of specialty chemicals for food, industrial, and consumer applications. The company produces polyglycerol esters, tall oil fatty acids, and polymer additives used in products like ice cream emulsifiers, paint driers, tire rubbers, and personal care formulations. Serving markets in aerospace components, beverages, cosmetics, and household cleaners, Emerald operates eight facilities across North America and Europe. Acquired by a private equity group in 2015, it focuses on bio-based chemistries and maintains supply chains linked to major brands in automotive and packaging sectors.
Emerald Kalama Chemical is a Rotterdam-headquartered global producer of specialty chemicals including benzoates, benzaldehydes, and plasticizers from facilities in Kalama, Washington, and Europe. The company supplies antimicrobials like Kalama KBA for paints, non-phthalate plasticizers for PVC flooring, and fragrance intermediates to clients such as Procter & Gamble and BASF, with annual capacity exceeding 100,000 metric tons.
IMD Natural Solutions is a developer of natural preservatives, antioxidants, and taste modifiers for food, beverage, and personal care products. The German firm produces AM-1 antimicrobial agents, AX-1 oil preservatives, and offers fermentation-based natural ingredient supply with R&D services for life sciences clients.
HQ CountryUnited StatesUnited StatesUnited StatesGermany
HQ City
New York City, NY
Cincinnati, OH
-
Dortmund
Deal Date24 Aug 202114 Feb 202114 Feb 20214 Apr 2018
Valuation$1B$1B$1B$36M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Lanxess acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by Lanxess

Lanxess has invested in 1 company to date.

Latest investment by Lanxess was on June 24th 2013. Lanxess invested in evocatal in their $5M Series B round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by Lanxess

evocatal
Description
evocatal is a German biocatalysis company producing enzymes and fine chemicals for pharmaceutical and chemical industries. Its evozymes catalog supports applications in textiles, detergents, nutrition, and cosmetics, while evochemicals provide chiral building blocks from grams to tons. Offering evoservices for custom biocatalytic processes, the firm is based in Halle, Germany, serving global industrial clients.
HQ CountryGermany
HQ City
Munich
Deal Date24 Jun 2013
RoundSeries B
Raised$5M
InvestorsHTGF (High-Tech Gruenderfonds); Lanxess; NRW.BANK; Roland Oetker; Saltigo; Sirius Seedfonds
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Lanxess investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Lanxess

When was Lanxess founded?Lanxess was founded in 2004.
Where is Lanxess headquartered?Lanxess is headquartered in Germany.
How many employees does Lanxess have?As of today, Lanxess has over 12K employees.
Is Lanxess publicly listed?Yes, Lanxess is a public company listed on Frankfurt Stock Exchange.
What is the stock symbol of Lanxess?Lanxess trades under LXS ticker.
When did Lanxess go public?Lanxess went public in 2005.
Who are competitors of Lanxess?Lanxess main competitors include FMC, Anupam Rasayan India, De Nora, CAC Nantong Chemical Co, Alpek, Ube, National Industralization, Ecovyst, Shanghai C&D Innostic, Advanced Petrochemical.
What is the current market cap of Lanxess?Lanxess' current market cap is $2B.
What is the current revenue of Lanxess?Lanxess' last 12 months revenue is $7B.
What is the current revenue growth of Lanxess?Lanxess revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of Lanxess?Current revenue multiple of Lanxess is 0.7x.
What is the current EBITDA of Lanxess?Lanxess' last 12 months EBITDA is $586M.
What is Lanxess' EBITDA margin?Lanxess' last 12 months EBITDA margin is 9%.
What is the current EV/EBITDA multiple of Lanxess?Current EBITDA multiple of Lanxess is 7.5x.
What is the current FCF of Lanxess?Lanxess' last 12 months FCF is ($21M).
What is Lanxess' FCF margin?Lanxess' last 12 months FCF margin is (0%).
What is the current EV/FCF multiple of Lanxess?Current FCF multiple of Lanxess is (208.3x).
How many companies Lanxess has acquired to date?As of June 2026, Lanxess has acquired 6 companies.
What was the largest acquisition by Lanxess?$3B acquisition of Chemtura Corporation on 25th September 2016 was the largest M&A Lanxess has done to date.
What companies Lanxess acquired?Lanxess acquired Chemtura Corporation, International Flavors & Fragrances, Emerald Performance Materials, Emerald Kalama Chemical, Chemours (clean and disinfect unit), and IMD Natural Solutions.
In how many companies Lanxess has invested to date?As of June 2026, Lanxess has invested in 1 company.
In what companies Lanxess invested in?Lanxess invested in evocatal.

See public comps similar to Lanxess

Lists including Lanxess

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial